What are the responsibilities and job description for the Director, Value & Evidence Strategy position at Alnylam Pharmaceuticals?
Overview
We are seeking a highly motivated and experienced Health Economics and Outcomes Research (HEOR) Lead to support our growing pipeline of RNAi assets. This individual will be responsible for developing and executing the HEOR strategy to demonstrate the value of our pipeline assets, inform strategic decision-making, and support market access efforts.
Key Responsibilities
- Develop and implement comprehensive HEOR strategic evaluations of pipeline programs, including unmet needs assessments, from a payer perspective.
- Design, implement, and oversee economic models, real-world evidence (RWE) studies to support the value story, and patient-reported outcome (PRO) assessments.
- Collaborate cross-functionally with internal stakeholders, including clinical development, regulatory, medical affairs, and commercial teams, to integrate HEOR insights into the clinical development plans.
- Engage with external stakeholders, including payers, key opinion leaders (KOLs), and patient advocacy groups, to understand evidence requirements and optimize data generation strategies.
- Collaborate cross-functionally to develop key value messages and an integrated evidence plan that aligns with market access, medical, and commercial strategies.
- Stay abreast of evolving HEOR methodologies, regulatory requirements, and market access landscapes specific to neurology and other indications.
- Engage with key opinion leaders, academic institutions, and industry partners to support study design, execution, and dissemination of HEOR studies.
- Lead the development of value dossiers (GVD, AMCP) and health technology assessment (HTA) submissions to support reimbursement and market access efforts globally.
Qualifications
About Alnylam : Alnylam Pharmaceuticals (Nasdaq : ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture : Our people-first culture is guided by our core values : fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.
